Dihydrotestosterone (DHT) (referred to as androstanolone or stanolone when used medically) can also be used in place of testosterone as an androgen. The availability of DHT is limited; it is not available in the United States or Canada, for instance, but it is available in certain European countries, including the United Kingdom , France , Spain , Belgium , Italy , and Luxembourg .  DHT is available in formulations including topical gel, buccal or sublingual tablets, and as esters in oil for intramuscular injection.  Relative to testosterone, and similarly to many synthetic AAS, DHT has the potential advantages of not being locally potentiated in so-called androgenic tissues that express 5α-reductase (as DHT is already 5α-reduced) and of not being aromatized into an estrogen (it is not a substrate for aromatase).
This web site is a repository of publicly available information, and is not intended to form a physician-patient relationship with any individual. The content of this website is for informational purposes only. The information presented on this web site is not intended to take the place of your personal physician’s advice and is not intended to diagnose, treat, cure or prevent any disease. Discuss this information with your own physician or healthcare provider to determine what is right for you. All information is intended for your general knowledge only and is not a substitute for medical advice or treatment for specific medical conditions. The information contained herein is presented in summary form only and intended to provide broad consumer understanding and knowledge. The information should not be considered complete and should not be used in place of a visit, call, consultation or advice of your physician or other health care provider. Only a qualified physician in your state can determine if you qualify for and should undertake treatment.
3) D Simon, MA Charles, K Nahoul, G Orssaud, J Kremski, V Hully, E Joubert, L Papoz, E Eschwege. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The telecom study. Journal of Clinical Endocrinology and Metabolism 82:2(FEB 1997):682-685. Some doctors give the low dose injections of 25 mg of testosterone cypionate or enanthate every 2 weeks. The treatment for men who have almost no testosterone is 10 times that dosage. A normal male produces the equivalent of 100 mg of testosterone (enanthate) each week.